Literature DB >> 2040354

Factors influencing the clinical response to surfactant replacement therapy in babies with severe respiratory distress syndrome. Collaborative European Multicentre Study Group.

.   

Abstract

Clinical data from a total of 164 babies with severe respiratory distress syndrome treated with a single dose of porcine surfactant (Curosurf, 200 mg/kg body weight) were subjected to multiple regression analysis in order to identify factors influencing the response to replacement therapy. At entry all babies were being treated with artificial ventilation, requiring at least 60% oxygen; the first 77 babies were part of a controlled trial, and an additional 87 babies were treated without controls once the benefit of surfactant therapy had been established. Both series of patients showed a sustained doubling of the mean arterial/alveolar oxygen tension ratio (a/APO2) after treatment with surfactant. Mortality was only 15% in the new series of treated patients, and the number of survivors without evidence of chronic lung disease after 28 days remained twice as high as that of the control group in the randomized study (55% vs. 26%; P less than 0.001). High fraction of inspired oxygen requirement at entry had a negative impact on a/APO2 6 h and 24 h after treatment. The duration of artificial ventilation and total time in greater than 21% oxygen were lower in heavier babies, who also had a lower mortality. Male and outborn babies had a higher mortality. Perinatal asphyxia (Apgar score less than 7 at 5 min) and high airway pressure requirement at entry were associated with increased mortality. Hospital allocation had a significant impact on all dependent variables. We also analysed the incidence of complications in relation to the therapeutic response pattern.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2040354     DOI: 10.1007/bf02093727

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  14 in total

1.  Gas exchange and lung morphology after surfactant replacement in experimental adult respiratory distress syndrome induced by repeated lung lavage.

Authors:  P Berggren; B Lachmann; T Curstedt; G Grossmann; B Robertson
Journal:  Acta Anaesthesiol Scand       Date:  1986-05       Impact factor: 2.105

2.  Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group.

Authors: 
Journal:  Pediatrics       Date:  1988-11       Impact factor: 7.124

3.  Factors associated with surfactant treatment response in infants with severe respiratory distress syndrome.

Authors:  A Charon; W Taeusch; C Fitzgibbon; G B Smith; S T Treves; D S Phelps
Journal:  Pediatrics       Date:  1989-03       Impact factor: 7.124

4.  Radiographic features of pulmonary oxygen toxicity in the newborn: Bronchopulmonary dysplasia.

Authors:  W H Northway; R C Rosan
Journal:  Radiology       Date:  1968-07       Impact factor: 11.105

5.  Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease.

Authors:  J D Gitlin; R F Soll; R B Parad; J D Horbar; H A Feldman; J F Lucey; H W Taeusch
Journal:  Pediatrics       Date:  1987-01       Impact factor: 7.124

6.  Is chronic lung disease in low birth weight infants preventable? A survey of eight centers.

Authors:  M E Avery; W H Tooley; J B Keller; S S Hurd; M H Bryan; R B Cotton; M F Epstein; P M Fitzhardinge; C B Hansen; T N Hansen
Journal:  Pediatrics       Date:  1987-01       Impact factor: 7.124

7.  Severe neonatal respiratory distress syndrome treated with the isolated phospholipid fraction of natural surfactant.

Authors:  G Noack; P Berggren; T Curstedt; G Grossmann; P Herin; W Mortensson; R Nilsson; B Robertson
Journal:  Acta Paediatr Scand       Date:  1987-09

8.  Epidemiology and classification of acute, neonatal respiratory disorders. A prospective study.

Authors:  O Hjalmarson
Journal:  Acta Paediatr Scand       Date:  1981-11

9.  A multicenter randomized, placebo-controlled trial of surfactant therapy for respiratory distress syndrome.

Authors:  J D Horbar; R F Soll; J M Sutherland; U Kotagal; A G Philip; D L Kessler; G A Little; W H Edwards; D Vidyasagar; T N Raju
Journal:  N Engl J Med       Date:  1989-04-13       Impact factor: 91.245

10.  Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial.

Authors:  M Hallman; T A Merritt; A L Jarvenpaa; B Boynton; F Mannino; L Gluck; T Moore; D Edwards
Journal:  J Pediatr       Date:  1985-06       Impact factor: 4.406

View more
  6 in total

1.  A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.

Authors:  H Walti; M Monset-Couchard
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

Review 2.  Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome.

Authors:  L R Wiseman; H M Bryson
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

3.  Mechanisms of bilirubin toxicity.

Authors:  M Amato
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

4.  Correlations between radiological and cytological findings in early development of bronchopulmonary dysplasia.

Authors:  G Noack; W Mortensson; B Robertson; R Nilsson
Journal:  Eur J Pediatr       Date:  1993-12       Impact factor: 3.183

5.  Intracerebral haemorrhages in surfactant treated neonates with severe respiratory distress syndrome: age at diagnosis, severity and risk factors.

Authors:  E Herting; O Gefeller; C P Speer; K Harms; H L Halliday; T Curstedt; B Robertson
Journal:  Eur J Pediatr       Date:  1994-11       Impact factor: 3.183

6.  Effect of surfactant and partial liquid ventilation treatment on gas exchange and lung mechanics in immature lambs: influence of gestational age.

Authors:  Carmen Rey-Santano; Victoria Mielgo; Elena Gastiasoro; Adolfo Valls-i-Soler; Xabier Murgia
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.